Cargando…
Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
The COVID-19 pandemic is ongoing, and the need for safe and effective vaccines to prevent infection and to control spread of the virus remains urgent. Here, we report the development of a SARS-CoV-2 subunit vaccine candidate (Betuvax-CoV-2) based on RBD and SD1 domains of the spike (S) protein fused...
Autores principales: | Krasilnikov, Igor V., Kudriavtsev, Aleksandr V., Vakhrusheva, Anna V., Frolova, Maria E., Ivanov, Aleksandr V., Stukova, Marina A., Romanovskaya-Romanko, Ekaterina A., Vasilyev, Kirill A., Mushenkova, Nataliya V., Isaev, Artur A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782008/ https://www.ncbi.nlm.nih.gov/pubmed/35062730 http://dx.doi.org/10.3390/vaccines10010069 |
Ejemplares similares
-
SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study
por: Vakhrusheva, Anna V., et al.
Publicado: (2022) -
Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial
por: Kudriavtsev, Aleksandr V., et al.
Publicado: (2023) -
IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice
por: Pulkina, Anastasia, et al.
Publicado: (2023) -
Enhancement of the Local CD8(+) T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens
por: Vasilyev, Kirill, et al.
Publicado: (2021) -
Mucosal Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens Provides Protection against Mycobacterium tuberculosis in Mice and Guinea Pigs
por: Sergeeva, Mariia, et al.
Publicado: (2021)